Authors

Latest:

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Abdulraheem Yacoub, MD

Latest:

Exploring the Future of MF Treatment

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Abhinav Deol, MD

Latest:

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Abigail L. Stockham, MD

Latest:

The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Abigail S. Caudle, MD

Latest:

Dr. Caudle on Upcoming Breast Cancer Trial Results

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Abraham Chachoua, MD

Latest:

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

â€‹Carmela Hoefling, RN, MSN, APN-C, AOCNP

Latest:

Carmela Hoefling Discusses Effects of Malnutrition During Surgery

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.

Adam Brufsky,MD

Latest:

Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.

Adam Brufsky, MD, Pittsburgh

Adam D. Cohen, MD

Latest:

Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple Myeloma

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Adam Dicker, MD, PhD

Latest:

Dr. Adam Dicker on Combination Treatments With Radiation Therapy

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the potential for radiation combinations.

Adam Feldman, MD

Latest:

Dr. Feldman on Link Between Obesity and Risk for RCC

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).

Adam H. Buchanan, MS, MPH, LGC

Latest:

Future of Multi-Cancer Early Detection: A Recap and Horizon

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Adam I. Riker, MD

Latest:

Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Adam J. Waxman, MD, MS

Latest:

Dr. Waxman on the Future of Treatment in Multiple Myeloma

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Adam M. Brufsky, MD

Latest:

Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD

Latest:

Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.

Adam M. Brufsky, MD, PhD, FACP, University of Pittsburgh

Adam M. Brufsky, MD, PhD, FACP, University of Pittsburgh School of Medicine

Adam M. Brufsky, MD, PhD, M University of Pittsburgh